The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
DNA Repair Capacity and Response to Treatment of Colon Cancer
Abstract
DNA repair, a complex biological process, ensures genomic integrity. Alterations in DNA repair, occurring in many cancers, contribute to the accumulation of mutations in the genome, resulting in genomic instability and cancer progression. DNA repair also plays a substantial role in response to chemotherapeutics: rapidly dividing colon cancer cells, vulnerable to DNA-damaging agents and overcoming DNA repair, undergo cell death. DNA repair capacity represents a complex biomarker, integrating gene variants, gene expressions, the stability of gene products, the effect of inhibitors/stimulators, lifestyle and environmental factors. Here, we discuss DNA repair capacity in sporadic colon cancer, a frequent malignancy worldwide, in relation to tumor heterogeneity, prognosis and prediction, measurements in surrogate and target tissues and suggest important tasks to be addressed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, patients with altered DNA repair capacity showed greater benefits from treatment with oxaliplatin54,57.”
From Self-supervised learning reveals clinically relevant histomorphological patterns for therapeutic strategies in colon cancer (2025) · cites this paper as [57]
Citations
Cites
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Therapeutic opportunities within the DNA damage response
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3891 · Cited by 587
Flagged first, then by citations
Research works printed but not linked: 56
- 10.3322/caac.21492 · DOI · Paper page
- 10.1158/1078-0432.CCR-04-0031 · DOI
- 10.1016/j.ejso.2014.11.001 · DOI
- Uk CR . Cancer Research UK. Bowel Cancer Incidence Statistics (2015). www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence
- 10.1056/NEJMsr1714643 · DOI
- 10.1111/j.1365-2559.2006.02549.x · DOI
- 10.1038/nature11252 · DOI · Paper page
- 10.1038/nm.3967 · DOI · Paper page
- 10.1093/annonc/mdt354 · DOI
- 10.1038/nrc1074 · DOI · Paper page
- 10.1016/j.critrevonc.2017.08.006 · DOI
- 10.1266/ggs.15-00023 · DOI
- 10.1016/j.dnarep.2018.08.010 · DOI
- 10.1177/1758834015614530 · DOI
- 10.1056/NEJMoa1500596 · DOI · Paper page
- 10.1093/annonc/mdy085 · DOI
- 10.1093/annonc/mdy410 · DOI
- 10.18632/oncotarget.24617 · DOI
- 10.1073/pnas.1401182111 · DOI
- 10.1111/cas.12366 · DOI
- 10.1016/j.cell.2011.02.013 · DOI · Paper page
- 10.1038/nrc3399 · DOI · Paper page
- 10.1038/nrc.2015.2 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-0247 · DOI
- 10.1016/j.molcel.2015.10.040 · DOI
- 10.1186/s12885-016-2826-8 · DOI
- 10.1007/s00018-008-8557-5 · DOI
- 10.1038/ncomms3674 · DOI
- 10.1016/j.dnarep.2014.03.030 · DOI · Paper page
- 10.18632/oncotarget.14909 · DOI
- 10.1053/j.gastro.2007.09.003 · DOI
- 10.1007/s11864-015-0348-2 · DOI
- 10.1093/annonc/mdx030 · DOI
- 10.1016/j.dnarep.2015.11.026 · DOI
- 10.1073/pnas.0438031100 · DOI
- 10.2217/pgs-2015-0017 · DOI
- 10.1002/mc.22141 · DOI
- 10.1093/mutage/ger070 · DOI
- 10.1016/j.dnarep.2014.03.009 · DOI
- 10.1158/0008-5472.CAN-16-1151 · DOI
- 10.1016/j.dnarep.2018.04.007 · DOI
- 10.1093/nar/gkz171 · DOI
- 10.1002/em.20650 · DOI
- 10.1016/j.dnarep.2018.09.006 · DOI
- 10.1158/1078-0432.CCR-08-3268 · DOI
- 10.1158/1078-0432.CCR-12-1380 · DOI
- 10.1016/j.tiv.2009.10.013 · DOI
- 10.1016/j.mrfmmm.2013.04.002 · DOI
- 10.1093/mutage/ges021 · DOI
- 10.1016/j.ijheh.2018.07.003 · DOI
- 10.1016/j.dnarep.2014.01.016 · DOI
- 10.1016/j.mrfmmm.2011.03.005 · DOI
- 10.1002/em.20055 · DOI
- 10.1289/ehp.6849 · DOI
- 10.1158/1078-0432.CCR-13-0314 · DOI
- 10.1016/j.clon.2019.02.007 · DOI
Cited by
Sorted by citations
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Self-citationLiu, B., Polack, M., Coudray, N., Claudio Quiros, A., Sakellaropoulos, T., Le, H., Karimkhan, A., Crobach, A. S. L. P., van Krieken, J. H. J. M., Yuan, K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57541-y · Cited by 25
“Interestingly,patientswithalteredDNArepaircapacityshowedgreater bene fi ts from treatment with oxaliplatin 54,57 .”
Metadata
- Authors
- Vodicka, P., Vodenkova, S., Buchler, T., & Vodickova, L.
- Affiliations
- Department of Molecular Biology of Cancer, Institute of Experimental Medicine, The Czech Academy of Sciences, Prague, Czech Republic
- Department of Oncology, First Faculty of Medicine, Charles University & Thomayer Hospital, Prague, Czech Republic
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2019-11
- Volume
- 20
- Issue
- 17
- Pages
- 1225-1233
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2983799111
- Cited by
- 19
- References
- 4
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 1 · 2023: 1 · 2022: 4 · 2021: 3 · 2020: 4 · 2019: 1
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacogenomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- GACR (18-09709S)
- Algemene Ziektekosten Verzekerin (15-27580A, NV18-00199)
- Charles University Research Centre program (UNCE/MED/006)
- Charles University Research (Q39, Q28)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- DNA repair capacity, colon cancer, chemosensitivity, genomic instability, tumor heterogeneity, prognostic factors, predictive biomarkers, DNA-damaging agents, surrogate tissue, tumor-infiltrating immune cells
- MeSH terms
- Colonic Neoplasms, DNA Damage, DNA Repair, Humans, Mutation, Prognosis, Gene Expression Regulation, Neoplastic, Cell Death, Genomic Instability, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
